Cancer and Enzymes
last updated 8.25.05
Enzymes have been used extensively in various forms of cancer. One reason is because of the multitude ways enzymes help in human health. Below is summary:
Pharmacological effects of oral enzyme combinations
Stauder G. Enzyme Research Medical Society, Geretsried, Germany. Cas Lek Cesk. 1995 Oct 4;134(19):620-4. PMID: 7585874 [PubMed - indexed for MEDLINE]
Combinations of hydrolytic enzymes have been used for therapy of variety of diseases for a long time, their pharmacology, however, is being recognized only in the course of last decades. In the article, the following pharmacological effects of combinations of oral hydrolytic enzymes are reviewed:
- activation of macrophages and NK cells,
- modulation of adhesion molecules, cytokines and immune complexes
Pharmacological effects are classified on four levels:
A spectrum of indications of enzyme therapy is inferred from the pharmacological effects: inflammations, traumatological events, surgical interventions, autoimmune and immune complex diseases, rheumatological diseases, viral infections, and malignant tumors.
Here is another discussion about enzymes used in cancer.
Enzyme Therapy in Oncology
Here is a review of the various ways bromelain works
Bromelain: A Literature Review and Discussion of its Therapeutic Applications
Description of multiple functions of enzymes
Everything You Learned About Enzymes Was Wrong
For discussions and references on how enzymes enhance immune system function:
see Enzymes and Immune System
see Enzymes and Viruses
see Leaky Gut
Bromelain can break down fibrin that is hiding viruses and bacteria. Once released anti-viral can become more affective. Any way lumbrokinase has become the recent enzyme of choice to break down the fibrin.
This is one of the things mentioned in the Enzymes for Autism and Enzymes for Digestive Health books, and it has been known for many, many years. This is one of the reasons enzymes therapy is so favored for viral diseases including stealth, HIV, and herpes. Cancer treatments have included digestive enzymes since the 1900 for the reason you mentioned - it breaks down the fibrin and other 'clots'. And why enzymes between meals help with fibromyalgia, chronic fatigue, vascular diseases, and other things. It cleans out the junk and clots building up in the body.
Here is a link that gives a basic description of lumbrokinase.
There are government trials going on investigating an 'alternative' approach to pancreatic cance which includes pancreatic enzymes as a key point. Read about this program at: Gonzalez Regimen and Trial description. Gonzalez web site: http://www.dr-gonzalez.com.
The mechanism of how this works is given in the books:
Enzymes – The Fountain of Life
by D.A. Lopez, M. Williams, and Miehlke. The Neville Press.
Charleston, South Carolina. 1994
Enzymes & Enzyme Therapy: How to Jump-Start Your Way to Lifelong
by Anthony J. Cichoke. Keats Publishing. 1994
FDA Grants Orphan Drug to Wobe-Mugos for Multiple Myeloma
Scottsdale, AZ - August 10, 2000 - The FDA has approved the Orphan Drug application of Wobe-Mugos as an adjunct therapy for multiple myeloma. Wobe-Mugos is a combination of systemic enzymes, used successfully in Europe in conjunction with chemotherapy since 1977.
Numerous clinical trials have proven its efficacy in reducing the severity of symptoms, extending life span and improving the quality of life of multiple myeloma patients.
The orphan drug application was filed by Marlyn Nutriceuticals of Scottsdale, AZ. The company conducts extensive in-house research and also collaborates with numerous leading research institutions around the world to develop safe, effective, and wholesome solutions to healthcare problems.
Each year, roughly 13,000 Americans develop multiple myeloma, an incurable form of cancer. The disease is characterized by the spread of cancerous B-Lymphocytes, the antibody-producing cells of the body. There is no cure. Currently, the only treatment is chemotherapy, and in some, bone marrow transplant.
Thanks to Oncology Today and Annie Appleseed Project for this information.
Induction of tumor necrosis factor in human peripheral-blood mononuclear cells by proteolytic enzymes.
Desser L, Rehberger A. Institute of Experimental and Applied Oncology, University of Vienna, Austria. Oncology. 1990;47(6):475-7. PMID: 2243666
We could demonstrate that polyenzyme preparations as well as bromelain and papain stimulate the production of tumor necrosis factor-alpha in human peripheral-blood mononuclear cell cultures in a time-dependent manner. We give evidence that immunomodulation and especially the release of cytokines may contribute to the therapeutic effect of these preparations.
[The use of enzymes in treating patients with malignant lymphoma with a large tumor mass]
Gubareva AA. Lik Sprava. 1998 Aug;(6):141-3. PMID: 9844901
Systemic enzymes (wobenzime and wobe-mugos) were approved, that had been prescribed as part of polychemotherapy to 24 patients with malignant lymphomas, who presented with large masses of lymphatic nodes poorly resorbable against the background of polychemotherapy and who were assigned for a high-total dose irradiation, which fact would undoubtedly entail sclerosing of adjacent intact tissues. The use of the enzymes made for the optimum realization of the polychemotherapy effect and permitted avoiding a good many of undesirable side events and complication thereof. The above systemic enzymes are well tolerated by patients; they induce no significant changes in the cellular composition or in blood biochemical indices.
[The adaptational properties and immunoregulatory action of a preparation of proteolytic enzymes in experimental stress]
Suzdal'nitskii RS, Levando VA, Emel'ianov BA, Sokolov IaA. Research Institute of Physical Training, Moscow, Russia. Zh Mikrobiol Epidemiol Immunobiol. 1999 Sep-Oct;(5):103-6. PMID: 10852034
The use of the experimental model of the development of acute secondary immunodeficiency, accompanied by the redistribution of immunoglobulins from plasma to blood cells, for evaluating the effect of immunomodulation is substantiated. The preparation of proteolytic enzymes Wobenzym [correction of "Vobenzyme"] has been shown to produce significant and dose-dependent decrease the sorption of immunoglobulins on mouse cells in the process of swimming.
[Density of adhesive proteins after oral administration of proteolytic enzymes in multiple myeloma]
Sakalova A, Kunze R, Holomanova D, Hapalova J, Chorvath B, Mistrik M, Sedlak J. Klinika hematologie a transfuziologie FN a Subkatedra hematologie a transfuziologie IVZ, Bratislava. Vnitr Lek. 1995 Dec;41(12):822-6. PMID: 8600653
The authors present information on the presence of adhesive proteins on membranes of myeloma and precursor cells isolated from bone marrow and blood from a group of 33 patients examined by fluorescent flow cytometry. They also compare the density of integrins (CD29, CD49e, CD41, CD51 and CD61) and adhesive proteins from the group of "homing" receptors (CD44) and IgG "superfamily" (LFA-1, LFA-3, ICAM-1, N-CAM) and their changes after a single oral dose of a mixture of proteolytic enzymes (Wobe Mugos, Wobenzym, MUCOS Pharma, FRG). The authors observed a significant drop of CD29, CD54 (ICAM-1), CD58 (LFA-3) after Wobe Mugos, CD49, CD51, CD58 after Wobenzyme. The insignificant decline of density of CD44 on cells, as well as of the soluble receptor of CD44 after oral administration of proteolytic enzymes in serum, incl. the mentioned changes of integrins and other adhesive proteins, indicate the importance of enzyme preparations in the supporting treatment of malignant processes.
Influence of a complementary treatment with oral enzymes on patients with colorectal cancers--an epidemiological retrolective cohort study.
Popiela T, Kulig J, Hanisch J, Bock PR. Cancer Chemother Pharmacol. 2001 Jul;47 Suppl:S55-63. PMID: 11561874 [PubMed - indexed for MEDLINE]
PURPOSE: To evaluate the impact of postoperative treatment with an oral enzyme (OE) preparation given complementary to an antineoplastic therapy in patients with all stages of colorectal cancer.
CONCLUSION: Complementary treatment of colorectal cancer patients with OE improves their quality of life by reducing both the signs and symptoms of the disease and the adverse reactions associated with adjuvant antineoplastic therapies. This epidemiological retrolective cohort analysis provides evidence that patients may also benefit by a prolongation of survival time. OE were generally well tolerated.
Vestn Khir Im I I Grek. 2003;162(4):57-62. [Experimental evaluation of the wound healing dynamics] Minaev SV. PMID: 14569780
The experimental clinical investigation of the influence of systemic enzymotherapy on the course of the wound process was carried out in rats and in clinic. The rats of the experimental group have demonstrated more rapid debridement of the wound from blood clots and tissue detritus, intensive formation of granular tissue and its ripening. The experimental investigation has shown that using the preparation of systemic enzymotherapy (Vobenzyme) stimulates processes of healing at the expense of quicker changing the inflammation phases as well as prevents the development of early and late complications on the side of postoperative wounds. It was confirmed by clinical observations in 36 patients from 4 to 14 years of age.